Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2016;15:660. https://doi.org/10.1038/nrd.2016.178.
Google ScholarÂ
Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477:99–102. https://doi.org/10.1038/nature10358.
Google ScholarÂ
Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3:841–9. https://doi.org/10.1001/jamaoncol.2016.2064.
Google ScholarÂ
Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets. 2007;7:141–8. https://doi.org/10.2174/156800907780058817.
Google ScholarÂ
Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20:160–77. https://doi.org/10.1038/s41571-022-00719-w.
Google ScholarÂ
Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28:1630–9. https://doi.org/10.1038/s41591-022-01897-x.
Google ScholarÂ
Russell SJ, Bell JC, Engeland CE, McFadden G. Advances in oncolytic virotherapy. Commun Med. 2022;2:33. https://doi.org/10.1038/s43856-022-00098-4.
Google ScholarÂ
Li Q, Oduro PK, Guo R, Li R, Leng L, Kong X, et al. Oncolytic viruses: immunotherapy drugs for gastrointestinal malignant tumors. Front Cell Infect Microbiol. 2022;12:921534. https://doi.org/10.3389/fcimb.2022.921534.
Google ScholarÂ
Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019;7:6. https://doi.org/10.1186/s40425-018-0495-7.
Google ScholarÂ
Inoue T, Byrne T, Inoue M, Tait ME, Wall P, Wang A, et al. Oncolytic vaccinia virus gene modification and cytokine expression effects on tumor infection, immune response, and killing. Mol Cancer Ther. 2021;20:1481–94. https://doi.org/10.1158/1535-7163.Mct-20-0863.
Google ScholarÂ
Pelin A, Boulton S, Tamming LA, Bell JC, Singaravelu R. Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity. Expert Opin Biol Ther. 2020;20:1083–97. https://doi.org/10.1080/14712598.2020.1757066.
Google ScholarÂ
McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61:8751–7.
Google ScholarÂ
Gao C, Ying Q, Qiu Y, Ren N, Chen K, Zhou Y, et al. Oncolytic vaccinia virus harboring CLEC2A gene enhances viral replication and antitumor efficacy. Mol Ther Oncol. 2024;32:200823. https://doi.org/10.1016/j.omton.2024.200823.
Google ScholarÂ
Yu J, An N, Zhu J, Zhu B, Zhang G, Chen K, et al. AVL-armed oncolytic vaccinia virus promotes viral replication and boosts antitumor immunity via increasing ROS levels in pancreatic cancer. Mol Ther Oncol. 2024;32:200878. https://doi.org/10.1016/j.omton.2024.200878.
Google ScholarÂ
Zhu B, Hong Z, Zhu J, Yu J, Zhou Y, Chen K, et al. Oncolytic vaccinia virus encoding aphrocallistes vastus lectin suppresses the proliferation of gastric cancer cells. Hum Gene Ther. 2024;35:938–50. https://doi.org/10.1089/hum.2024.100.
Google ScholarÂ
Wang R, Hu M, Lozzi I, Jin CZJ, Ma D, Splith K, et al. Cytokine-armed vaccinia virus promotes cytotoxicity toward pancreatic carcinoma cells via activation of human intermediary CD56(dim)CD16(dim) natural killer cells. Int J Cancer. 2025;156:638–51. https://doi.org/10.1002/ijc.35209.
Google ScholarÂ
Azar F, Deforges J, Demeusoit C, Kleinpeter P, Remy C, Silvestre N, et al. TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment. J Immunother Cancer. 2024; 12. https://doi.org/10.1136/jitc-2024-009302
Wang N, Wang J, Zhang Z, Cao H, Yan W, Chu Y, et al. A novel vaccinia virus enhances anti-tumor efficacy and promotes a long-term anti-tumor response in a murine model of colorectal cancer. Mol Ther Oncolytics. 2021;20:71–81. https://doi.org/10.1016/j.omto.2020.11.002.
Google ScholarÂ
Chen L, Chen H, Ye J, Ge Y, Wang H, Dai E, et al. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation. Theranostics. 2021;11:6668–81. https://doi.org/10.7150/thno.56494.
Google ScholarÂ
Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther J Am Soc Gene Ther. 2012;20:749–58. https://doi.org/10.1038/mt.2011.276.
Google ScholarÂ
Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019;18:689–706. https://doi.org/10.1038/s41573-019-0029-0.
Google ScholarÂ
Martinez-Quintanilla J, Seah I, Chua M, Shah K. Oncolytic viruses: overcoming translational challenges. J Clin Investig. 2019;129:1407–18. https://doi.org/10.1172/jci122287.
Google ScholarÂ
Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O’Malley ME, Jones HL, et al. Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers. Mol Ther J Am Soc Gene Ther. 2016;24:1492–501. https://doi.org/10.1038/mt.2016.101.
Google ScholarÂ
Hwang J, Pallas DC. STRIPAK complexes: structure, biological function, and involvement in human diseases. Int J Biochem cell Biol. 2014;47:118–48. https://doi.org/10.1016/j.biocel.2013.11.021.
Google ScholarÂ
Shi Z, Jiao S, Zhou Z. STRIPAK complexes in cell signaling and cancer. Oncogene. 2016;35:4549–57. https://doi.org/10.1038/onc.2016.9.
Google ScholarÂ
Jeong BC, Bae SJ, Ni L, Zhang X, Bai XC, Luo X. Cryo-EM structure of the Hippo signaling integrator human STRIPAK. Nat Struct Mol Biol. 2021;28:290–9. https://doi.org/10.1038/s41594-021-00564-y.
Google ScholarÂ
Madsen CD, Hooper S, Tozluoglu M, Bruckbauer A, Fletcher G, Erler JT, et al. STRIPAK components determine mode of cancer cell migration and metastasis. Nat Cell Biol. 2015;17:68–80. https://doi.org/10.1038/ncb3083.
Google ScholarÂ
Triastuti E, Nugroho AB, Zi M, Prehar S, Kohar YS, Bui TA, et al. Pharmacological inhibition of Hippo pathway, with the novel kinase inhibitor XMU-MP-1, protects the heart against adverse effects during pressure overload. Br J Pharmacol. 2019;176:3956–71. https://doi.org/10.1111/bph.14795.
Google ScholarÂ
Wang Y, Li J, Gao Y, Luo Y, Luo H, Wang L, et al. Hippo kinases regulate cell junctions to inhibit tumor metastasis in response to oxidative stress. Redox Biol. 2019;26:101233. https://doi.org/10.1016/j.redox.2019.101233.
Google ScholarÂ
Kennedy BE, Sadek M, Gujar SA. Targeted metabolic reprogramming to improve the efficacy of oncolytic virus therapy. Mol Ther J Am Soc Gene Ther. 2020;28:1417–21. https://doi.org/10.1016/j.ymthe.2020.03.014.
Google ScholarÂ
Stuart SD, Schauble A, Gupta S, Kennedy AD, Keppler BR, Bingham PM, et al. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014;2:4 https://doi.org/10.1186/2049-3002-2-4.
Google ScholarÂ
Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol. 2020;20:537–51. https://doi.org/10.1038/s41577-020-0288-3.
Google ScholarÂ
Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10:26–39. https://doi.org/10.1158/2159-8290.Cd-19-0761.
Google ScholarÂ
Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer cell. 2020;38:167–97. https://doi.org/10.1016/j.ccell.2020.06.001.
Google ScholarÂ
Li L, Tan J, Miao Y, Lei P, Zhang Q. ROS and autophagy: interactions and molecular regulatory mechanisms. Cell Mol Neurobiol. 2015;35:615–21. https://doi.org/10.1007/s10571-015-0166-x.
Google ScholarÂ
Zheng Y, Pan D. The Hippo signaling pathway in development and disease. Dev cell. 2019;50:264–82. https://doi.org/10.1016/j.devcel.2019.06.003.
Google ScholarÂ
Ma S, Meng Z, Chen R, Guan KL. The Hippo pathway: biology and pathophysiology. Annu Rev Biochem. 2019;88:577–604. https://doi.org/10.1146/annurev-biochem-013118-111829.
Google ScholarÂ
Zhang Q, Zhang X, Lei X, Wang H, Jiang J, Wang Y, et al. Influenza A virus NS1 protein hijacks YAP/TAZ to suppress TLR3-mediated innate immune response. PLoS Pathog. 2022;18:e1010505. https://doi.org/10.1371/journal.ppat.1010505.
Google ScholarÂ
Lee JH, Kwon M, Lim WY, Yoo CR, Yoon Y, Han D, et al. YAP inhibits HCMV replication by impairing STING-mediated nuclear transport of the viral genome. PLoS Pathog. 2022;18:e1011007. https://doi.org/10.1371/journal.ppat.1011007.
Google ScholarÂ
Zhang H, Cui M, Tang D, Wang B, Liang G, Xu C, et al. Localization of cancer cells for subsequent robust photodynamic therapy by ROS responsive polymeric nanoparticles with anti-metastasis complexes NAMI-A. Adv Mater. 2024;36: e2310298. https://doi.org/10.1002/adma.202310298
Li K, Tian S, Sun K, Su Q, Mei Y, Niu W. ROS-responsive polyprodrug micelles carrying suicide genes in combination with chemotherapy and gene therapy for prostate cancer treatment. RSC Adv. 2024;14:5577–87. https://doi.org/10.1039/d4ra00352g.
Google ScholarÂ
